Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer | Zendy

Joanna Kłubo-Gwieździńska | Zendy; Sungyoung Auh | Zendy; Marvin C. Gershengorn | Zendy; Brianna Daley | Zendy; Athanasios Bikas | Zendy; Kenneth D. Burman | Zendy; Leonard Wartofsky | Zendy; Mark L. Urken | Zendy; Eliza H. Dewey | Zendy; Robert C. Smallridge | Zendy; Ana-Maria Chindris | Zendy; Electron Kebebew | Zendy

Open Access

Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer

Author(s) -

Joanna Kłubo-Gwieździńska,

Sungyoung Auh,

Marvin C. Gershengorn,

Brianna Daley,

Athanasios Bikas,

Kenneth D. Burman,

Leonard Wartofsky,

Mark L. Urken,

Eliza H. Dewey,

Robert C. Smallridge,

Ana-Maria Chindris,

Electron Kebebew

Publication year - 2019

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2018.7754

Subject(s) - medicine , levothyroxine , thyroid cancer , proportional hazards model , cohort , thyroidectomy , thyroid , oncology , gastroenterology

Key Points Question Is thyrotropin suppression associated with better outcomes in patients with intermediate- and high-risk differentiated thyroid cancer? Findings In this cohort study including 867 patients with intermediate- and high-risk differentiated thyroid cancer followed up for a mean (SD) of 7.2 (5.8) years, thyrotropin suppression was not associated with improved progression-free survival or overall survival. Meaning Patients with intermediate- and high-risk differentiated thyroid cancer might not benefit from thyrotropin suppression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research